Jon S. Fukumoto, MD
Clinical and Translational Research Program
University of Hawaii Cancer Center
- Assistant Clinical Professor
University of Hawaii
- MD, Medicine
New York University
- Residency, Internal Medicine
Los Angeles County-USC Medical Center
- Fellowship, Hematology
Stanford University Medical Center
I have an interest in clinical trials in hematologic malignancies. My previous experience has been in industry-sponsored trials, specifically in the use of novel agents to ameliorate anemia in myelodysplastic syndrome, including studies of 1) p38 MAP kinase inhibitor and 2) hypoxia inducible factor-1 stabilizer. As a member of the UH Cancer Center, I would be particularly interested in studies of novel agents and chemotherapy combinations for acute leukemia in the elderly and relapsed or refractory patients, where I think there is an unmet need.
- Fukumoto JS. (2008). The hematologist's approach to myelodysplastic syndrome. Hawaii Med J, 67:164, PMID18678209.
- Fukumoto JS, Gotlib J. (2006). A patient with paroxysmal nocturnal hemoglobinuria. T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance. Am J Hematol, 81:870, PMID16929542.
- Fukumoto JS, Greenberg PL. (2005)/ Management of patients with higher risk myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 56:179, PMID15979321.
- Smith DL, Cai J, Zhu ST, Wei W, Fukumoto J, Sharma S, Masood R, Gill PS. (2003). Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan. Int J Cancer, 106:528, PMID12845648.
Publication list via PubMed